Estimating Outcome in Patients with HIV-Related Lymphoma. Ann Intern Med. 2005;143:I-28. doi: 10.7326/0003-4819-143-4-200508160-00003
Download citation file:
Published: Ann Intern Med. 2005;143(4):I-28.
Human immunodeficiency virus (HIV) is the cause of AIDS, an illness that interferes with the ability to fight off infection and certain types of cancer. Since 1996, combinations of drugs, known as highly active antiretroviral therapy, or HAART, have been prescribed to decrease infections and cancer and lengthen life in many people with AIDS.
Lymphoma is a type of cancer that develops in lymph nodes, collections of immune cells that are present throughout the body. Lymphoma occurs in people who do not have HIV infection or AIDS, but it is more common in people with HIV or AIDS than in the general population.
The International Prognostic Index (IPI) is an index that helps doctors to predict survival of people with lymphoma. The IPI considers patient age, cancer stage, and laboratory tests. It is not known how well the IPI predicts survival in people with HIV-related lymphoma who are receiving HAART. Since HIV-related lymphoma is a common complication of HIV infection, it would be helpful to have a way to predict how patients with this cancer will do.
To see whether the IPI or other factors could help to predict survival in people with HIV-related lymphoma.
111 patients with HIV infection and lymphoma diagnosed since 1996.
The researchers collected information on the factors that make up the IPI, other patient characteristics, and laboratory values and developed mathematical models to see which combination of factors did the best job of predicting how long people lived.
The IPI index plus a laboratory value called CD4 cell count could separate patients into 4 groups that had 1-year survival rates of 82%, 47%, 20%, and 15%.
The study included only 111 patients who were taking a variety of different combinations of HIV drugs. It was not able to determine whether the type of HIV treatment was related to survival.
The IPI and CD4 cell count can help doctors predict the prognosis of patients with HIV-related lymphoma.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only